ACON AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
ACON Current Performance
5.85%
Aclarion inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to ACON
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
NEPH | Nephros inc | 4 | 3 | 3 | 1 | 1 | |
SNOA | Sonoma pharmaceuticals inc | 3 | 5 | 2 | 1 | 1 | |
IART | Integra lifesciences holdings corporation | 3 | 3 | 4 | 2 | 1 | |
RGEN | Repligen corporation | 4 | 3 | 4 | 2 | 1 | |
EMBC | Embecta corp | - | 3 | 2 | 3 | 1 |
- NEPH Nephros incValue 4Trend 3Swing Trading 3Whale Interest 1Dividend 1See more
ACON Profile
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. It has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that the Company has demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. It uses a magnet to apply a pulsed magnetic field to a patient, sensors to detect radio waves that emanate from the resonant vibrations of different chemicals in the body in response to that pulsed magnetic field and a computer to create detailed images of tissue structures in the patient based on those detected chemical signals.